NCT03398252

Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Participants (N=10/group) will consist of non-treatment seeking individuals with AUD. Following informed consent and baseline screening, participants will partake in 3 stress induction sessions to assess their stress levels and cravings for alcohol. Participants will be randomized to receive either increasing doses of doxazosin XL (0, 4, and 8 mg) or placebo in a double-blind manner.

Conditions

• Alcohol Use Disorder

Interventions

Type	Name	Description
DRUG	Doxazosin XL	Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
DRUG	Placebo	Participants will be randomized to receive a placebo for doxazosin XL.

Timeline

• Start date: 2022-05-12
• Primary completion: 2023-10-01
• Completion: 2023-10-01
• First posted: 2018-01-12
• Last updated: 2022-09-01

Regulatory

• FDA-regulated drug study